Dr. Sugimoto is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
800 S Wells St
Ste M15
Chicago, IL 60607Phone+1 312-431-6765Fax+1 312-431-7959
Education & Training
Rush University Medical CenterResidency, Internal Medicine, 1983 - 1986
Rush Medical College of Rush University Medical CenterClass of 1983
Certifications & Licensure
IL State Medical License 1983 - 2026- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Jun 18
- A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2014 Apr 01
- A Study of LY2623091 in Participants With High Blood Pressure Start of enrollment: 2014 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 209 citationsSemaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.Helena W. Rodbard, Ildiko Lingvay, John C. Reed, Raymond de la Rosa, Ludger Rose
The Journal of Clinical Endocrinology and Metabolism. 2018-06-01 - 6 citationsEffects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial.Jena Shaw Tronieri, Anthony N. Fabricatore, Thomas A. Wadden, Pernille Auerbach, Lars Endahl
Obesity Facts. 2020-11-16 - 76 citationsEfficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Contro...W. Timothy Garvey, Andreas L. Birkenfeld, Dror Dicker, Geltrude Mingrone, Sue D. Pedersen
Diabetes Care. 2020-03-03
Journal Articles
- Efficacy of iGlarLixi, a Fixed‐Ratio Combination of Insulin Glargine and Lixisenatide, in Patients with Type 2 Diabetes Stratified as High and Low Risk According to HE...Danny Sugimoto, MD, Diabetes, Obesity and Metabolism
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
